EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: Results of a randomised crossover study

British Journal of Ophthalmology

Volumn 100, Issue 6, 2016, Pages 843-847

  Berlin, Michael S ^a   Rowe Rendleman, Cheryl ^b   Ahmed, Ike ^c   Ross, Douglas T ^b   Fujii, Akifumi ^b   Ouchi, Takafumi ^b   Quach, Christine ^a   Wood, Andrew ^b   Ward, Caroline L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ONO PHARMACEUTICAL CO   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONO 9054; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; EYE DROPS; OXEPINE DERIVATIVE; PROPAN-2-YL 4-(6-(4-(2,5-DIFLUOROPHENOXY)-3-HYDROXYBUT-1-EN-1-YL)-7-HYDROXYOCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOATE; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EVENING DOSAGE; EYE EXAMINATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MORNING DOSAGE; OPEN ANGLE GLAUCOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; OXEPINS; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84971449553     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-307000     Document Type: Article

References (15)

1. Ishida N, Odani-Kawabata N, Shimazaki A, et al. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 2006;24:1-10.
2. National Institute for Health and Care Excellence (NICE). Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. https://www.nice.org.uk/guidance/cg85 (accessed 31 Mar 2015).
3. American Optometric Association (AOA). Optometric clinical practice guideline: Care of the patient with open angle glaucoma. 2011. http://www.aoa.org/documents/optometrists/CPG-9.pdf (accessed 31 Mar 2015).
4. Lin L, Zhao YJ, Chew PT, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother 2014;48:1585-93.
5. Lee A, McCluskey P. Chemical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology 2010;4:741-64.
6. Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci 2002;43:1475-87.
7. Gabelt BT, Hennes EA, Bendel MA, et al. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. Ocul Pharmacol Ther 2009;25:1-8.
8. Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054 - a novel dual agonist of prostanoid EP3 and FP receptors - in monkeys. Invest Ophthalmol Vis Sci 2015;56:2547-52.
9. Drance SM. Diurnal variation of intraocular pressure in treated glaucoma. Arch Ophthalmol 1963;70:302-11.
10. Sacca SC, Rolando M, Marletta A, et al. Fluctuations of intraocular pressure during the day in open angle glaucoma, normal tension glaucoma and normal subjects. Ophthalmologica 1998;212:115-19.
11. Zeimer RC, Wilensky JT, Gieser DK. Presence and rapid decline of early morning intraocular pressure peaks in glaucoma. Ophthalmology 1990;97:547-50.
12. Abelson MB, Ousler GW, Maffei C. Dry eye in 2008. Curr Opin Ophthalmol 2009;20:282-6.
13. Walker PM, Lane KJ, Ousler GW III, et al. Diurnal variation of visual function and the signs and symptoms of dry eye. Cornea 2010;29:607-12.
14. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
15. Dreer LE, Girkin C, Mansberger SL. Determinants of medication adherence to topical glaucoma therapy. J Glaucoma 2012;21:234-40.